LONG-TERM SAFETY OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER: RESULTS FROM THE ENGOT-OV16/NOVA TRIAL

Guidance on Monitoring and Management of Adverse Events and Dose Modifications With Ribociclib Treatment Based on Results From the MONALEESA Program

Efficacy and Safety of Ribociclib Combined With an Endocrine Partner in a Diverse Population With Advanced Breast Cancer

Consensus recommendations for management and counselling of adverse events associated with lorlatinib

New androgen antagonists in non-metastatic castration-resistant prostate cancer

Managing Adverse Events in Patients with Relapsed/Refractory Mantle Cell Lymphoma Treated with Acalabrutinib: Clinical Experience from the MD Anderson Center

Quality of Life in Cutaneous T-Cell Lymphoma Subjects Treated With Anti-CCR4 Monoclonal Antibody Mogamulizumab vs Vorinostat: Results from the Phase 3 MAVORIC Trial

Neratinib in patients with HER2-mutant cancers: findings from the SUMMIT trial

Effective management and prevention of diarrhea associated with the tyrosine kinase inhibitor neratinib: findings from the CONTROL study and individual patient cases

Nursing Best Practices for Moxetumomab Pasudotox-tdfk, a New Treatment for Hairy Cell Leukemia

Management of Treatment-Related Adverse Events in Patients Treated With Mogamulizumab: A Single-Center Experience

Phase III study (CANOPY-A) of canakinumab (ACZ885) as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC) – implications for nurses